The firm is testing the modified nucleotide drug ateganosine in a Phase II study with a PD-1 inhibitor in patients with non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback